<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<?covid-19-tdm?>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2024.1490478</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>
<italic>TLR10</italic> overexpression modulates immune response in A549 lung epithelial cells challenged with SARS-CoV-2 S and N proteins</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Knez</surname>
<given-names>&#x160;pela</given-names>
</name>
<uri xlink:href="https://loop.frontiersin.org/people/2806273"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/project-administration/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Narat</surname>
<given-names>Mojca</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ogorevc</surname>
<given-names>Jernej</given-names>
</name>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2339923"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/resources/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1">
<institution>Department of Animal Science, Biotechnical Faculty, University of Ljubljana</institution>, <addr-line>Ljubljana</addr-line>, <country>Slovenia</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Liliana Oliveira, Universidade do Porto, Portugal</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Karen Bohmwald, Autonomous University of Chile, Chile</p>
<p>S&#xed;lvia Vale-Costa, Universidade do Porto, Portugal</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Jernej Ogorevc, <email xlink:href="mailto:jernej.ogorevc@bf.uni-lj.si">jernej.ogorevc@bf.uni-lj.si</email>
</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>01</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1490478</elocation-id>
<history>
<date date-type="received">
<day>03</day>
<month>09</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>16</day>
<month>12</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2025 Knez, Narat and Ogorevc</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Knez, Narat and Ogorevc</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Toll-like receptors (TLRs) play an important role in the recognition of viral particles and activation of the innate immune system, but their role in SARS-CoV-2 infection is still poorly characterized. In the present study, we investigated the role of Toll-like receptor 10 (TLR10) in modulating the immune response during SARS-CoV-2 infection. The results showed that overexpression of <italic>TLR10</italic> in A549 lung epithelial cells, immunostimulated with SARS-CoV-2 proteins S and N mainly downregulated proinflammatory cytokines and interferons and affected gene expression in the cocultured THP-1 monocytes. Our results suggest that TLR10 could mediate the extent of SARS-CoV-2 infection by downregulating the release of inflammatory cytokines and chemokines such as <italic>CXCL10</italic>, <italic>IL6</italic>, <italic>IL8</italic>, and <italic>IFN&#x3b2;</italic>. Modulation of <italic>TLR10</italic> expression could have implications for the treatment of patients with severe COVID-19, in whom excessive inflammation leading to the development of acute respiratory distress syndrome (ARDS) is a key feature. However, further research is needed to fully understand the impact of modulating <italic>TLR10</italic> expression on the antiviral response and the overall balance of the immune response during SARS-CoV-2 infection.</p>
</abstract>
<kwd-group>
<kwd>SARS-CoV-2</kwd>
<kwd>COVID-19</kwd>
<kwd>Toll-like receptor 10</kwd>
<kwd>interferons</kwd>
<kwd>proinflammatory cytokines</kwd>
<kwd>innate immunity</kwd>
</kwd-group>
<counts>
<fig-count count="6"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="47"/>
<page-count count="11"/>
<word-count count="5347"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Molecular Innate Immunity</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a recently emerged virus that causes coronavirus disease 2019 (COVID-19). Since 2019, it has spread worldwide, affecting global health, social life and the world economy. SARS-CoV-2 is a &#x3b2;-coronavirus that belongs to the <italic>Coronaviridae</italic> family and is an enveloped positive-strand RNA (+ssRNA) virus. The virus consists of four main structural proteins, namely the spike glycoprotein (S), the small envelope glycoprotein (E), the membrane glycoprotein (M) and the nucleocapsid phosphoprotein (N), as well as several accessory proteins, such as the papain-like protease (P) (<xref ref-type="bibr" rid="B1">1</xref>).</p>
<p>Infection of the respiratory tract with SARS-CoV-2 leads to an extremely diverse clinical spectrum. It ranges from asymptomatic forms and mild symptoms such as fever, dry cough and shortness of breath to severe symptoms that require hospitalization. In the most severe cases of SARS-CoV-2 infection, acute overproduction and uncontrolled release of proinflammatory cytokines (hypercytokinemia, also known as &#x201c;cytokine storm&#x201d;) can trigger excessive systemic inflammation leading to acute respiratory distress syndrome (ARDS) and multiple organ failure (<xref ref-type="bibr" rid="B2">2</xref>). The severity of the disease has been associated with elevated levels of various proinflammatory cytokines and chemokines, such as interleukin (IL)1&#x3b2;, IL6, IL8, C-X-C motif chemokine ligand 10 (CXCL10), chemokine (C-C motif) ligand 20 (CCL20), tumor necrosis factor alpha (TNF&#x3b1;), and a delayed type I interferone (IFN) response (<xref ref-type="bibr" rid="B3">3</xref>&#x2013;<xref ref-type="bibr" rid="B6">6</xref>).</p>
<p>Airway epithelial cells interface with the external environment and play a key role in recognizing airborne pathogens and activating the host immune system (<xref ref-type="bibr" rid="B7">7</xref>). Pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs), which recognize pathogen-associated molecular patterns (PAMPs) and trigger an immune response, are important components of the innate immune system. Members of the TLR family are the best-studied PRRs that can also recognize structural proteins of SARS-CoV-2 (<xref ref-type="bibr" rid="B8">8</xref>). TLRs on endosomes recognize intracellular components of viruses; for example, TLR7 and TLR8 can recognize viral single-stranded RNA (<xref ref-type="bibr" rid="B9">9</xref>, <xref ref-type="bibr" rid="B10">10</xref>), TLR3 recognizes transient dsRNA intermediates formed during replication of the virus (<xref ref-type="bibr" rid="B11">11</xref>), while TLRs on the cell membrane recognize viral proteins. The S protein is thought to be recognized by both TLR2 (<xref ref-type="bibr" rid="B12">12</xref>) and TLR4 (<xref ref-type="bibr" rid="B13">13</xref>), while protein E is recognized by TLR2 (<xref ref-type="bibr" rid="B14">14</xref>). It has been shown that not only the viral infection but also various individual SARS-CoV-2 proteins are immunogenic both <italic>in vivo</italic> and <italic>in vitro</italic> (<xref ref-type="bibr" rid="B15">15</xref>) and trigger the expression of proinflammatory cytokines in immune (<xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B15">15</xref>) and epithelial cells (<xref ref-type="bibr" rid="B12">12</xref>).</p>
<p>TLR10 is the only poorly characterized member of the TLR family. It belongs to the TLR2 subfamily and can homodimerize in the presence of its respective ligands or act in paired combination with other members of the subfamily (TLR1, TLR2, TLR6) (<xref ref-type="bibr" rid="B16">16</xref>). To our knowledge, the role of TLR10 in the recognition of SARS-CoV-2 has not yet been investigated, but it is known that <italic>TLR10</italic> is expressed in lung epithelial cells (<xref ref-type="bibr" rid="B17">17</xref>). Our recent results confirmed that TLR10 is indeed present in A549 lung epithelial cells and showed that its overexpression by CRISPRa downregulates some of the proinflammatory mediators in cells immunostimulated with dsRNA, LPS or Pam3Cys (<xref ref-type="bibr" rid="B18">18</xref>). Studies also show that upregulation of <italic>TLR10</italic> is possible by adding the biologically active form of vitamin D, calcitriol (1,25-dihydroxycholecalciferol), to the cell growth medium (<xref ref-type="bibr" rid="B19">19</xref>). However, the effects of other vitamins (e.g. vitamin C and B vitamins) associated with the prevention and management of COVID-19 (<xref ref-type="bibr" rid="B20">20</xref>) on <italic>TLR10</italic> expression in cell cultures have not been determined. As several vitamins, especially D and C, have been associated with the prevention and treatment of diseases, including SARS-CoV-2 infections (e.g. <xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>), we were interested in whether the addition of vitamins to the growth medium affects <italic>TLR10</italic> expression; if so, one could speculate that the immunomodulatory effects of vitamins could be explained, at least in part, by their effect on the regulation of TLR10 expression.</p>
<p>The aim of this study was to investigate the potential immunoregulatory effects of <italic>TLR10</italic> upregulation in the A549 cell line immunostimulated with SARS-CoV-2 S and N proteins. To our knowledge, this is one of the first studies to address the potential immunomodulatory effects of TLR10 in lung epithelial cells during immunostimulation with SARS-CoV-2 proteins in an <italic>in vitro</italic> system. Harnessing the immunomodulatory effects of TLR10 could have potential therapeutic applications for the treatment of patients with severe COVID-19 as well as for the management of other inflammatory diseases.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<label>2</label>
<title>Materials and methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Cell culture</title>
<p>The human lung epithelial cell line A549 was purchased from the American Type Culture Collection (ATCC). Cells were grown in DMEM (Sigma Aldrich) supplemented with 10% FBS (Sigma&#x2013;Aldrich), 2 mM L-glutamine (Thermo Fisher Scientific), and 0.01% penicillin-streptavidin (Sigma&#x2013;Aldrich) at 37&#xb0;C and 5% CO<sub>2</sub>.</p>
<p>The human mononuclear cell line THP-1 (ATCC) was grown in RPMI 1640 medium (Sigma&#x2013;Aldrich) supplemented with 10% FBS (Sigma&#x2013;Aldrich) and 0.01% penicillin-streptavidin (Sigma&#x2013;Aldrich) at 37&#xb0;C and 5% CO<sub>2</sub>.</p>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>
<italic>TLR10</italic> overexpression</title>
<p>Endogenous <italic>TLR10</italic> was overexpressed in A549 cells with CRISPR/dCas9 as previously described (<xref ref-type="bibr" rid="B18">18</xref>). Briefly, cells were transfected using Lipofectamine 3000 (Thermo Fisher Scientific) at approximately 70% confluence with the vectors pCMV-dCas9:NLS: VPR (<xref ref-type="bibr" rid="B23">23</xref>), encoding dCas9-VPR, and pGGAselect (N0309AAVIAL, New England BioLabs), encoding sgRNAs for <italic>TLR10</italic> overexpression, (A549-TLR10<sub>OE</sub>) or with an empty pGGAselect vector representing <italic>TLR10</italic> control expression (A549<sub>C</sub>). To avoid cell apoptosis, cells were washed with PBS four hours after transfection, and the medium was changed. All experiments were performed 48 hours after transfection. Localization of TLR10 in A549<sub>C</sub> and A549-TLR10<sub>OE</sub> was determined using immunostaining (see <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Section S4</bold>
</xref>).</p>
<p>In addition, ascorbic acid (A4544, Merck), folic acid (F8758, Merck), calciferol (D1530, Merck) and riboflavin (R9504, Merck) were added to the growth medium of non-transfected A549 cells at two different concentrations (50 or 200 &#xb5;M) to determine their effects on <italic>TLR10</italic> expression after 24 and 48 hours of incubation.</p>
</sec>
<sec id="s2_3">
<label>2.3</label>
<title>Immunostimulation of A549 cells</title>
<p>Cells were immunostimulated with final concentrations of 500 ng/mL SARS-CoV-2 protein S (RP87668, Thermo Fisher Scientific) or SARS-CoV-2 protein N (RP87707, Thermo Fisher Scientific) and incubated for four and 24 hours (corresponding to &#x201c;early&#x201d; and &#x201c;late&#x201d; immune response, respectively) to simulate immune challenge of lung epithelial cells during SARS-CoV-2 infection. RNA was extracted from the cells and gene expression was quantified by real-time PCR. In addition, the growth media were collected for the quantification of cytokines.</p>
</sec>
<sec id="s2_4">
<label>2.4</label>
<title>Co-culture of stimulated A549-TLR10<sub>OE</sub> cells and THP-1 cells</title>
<p>Cells were plated on 12 mm Transwell&#x2122; plates with 0.4 &#x3bc;m pore polyester membrane inserts (3460, Corning). One day before transfection, A549 cells were seeded at a concentration of 1&#xd7;10<sup>5</sup> cells/well in the upper chamber of the Transwell system (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>). On the day of transfection, cells were transfected with pCMV-dCas9:NLS: VPR and pGGAselect as described above to obtain A549-TLR10<sub>OE</sub> and A549<sub>C</sub> cells. After four hours of incubation, the cells were washed with PBS and the medium was changed. After two days, THP-1 cells were seeded into the lower chamber at a concentration of 0.5&#xd7;10<sup>6</sup> cells/well. A549-TLR10<sub>OE</sub> and A549<sub>C</sub> cells were stimulated with SARS-CoV-2 S or N protein at a final concentration of 500 ng/mL for four or 24 hours, respectively. The cell culture medium was collected and RNA was isolated from THP-1 cells as described above.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Schematic representation of the co-culture experiments involving A549 and THP-1 cells in a transwell system.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1490478-g001.tif"/>
</fig>
</sec>
<sec id="s2_5">
<label>2.5</label>
<title>RNA isolation and cDNA library preparation</title>
<p>Total RNA was isolated using the RNeasy Mini Kit (Qiagen) according to the manufacturer&#x2019;s instructions. The extracted RNA was diluted to a final concentration of approximately 100 ng/&#xb5;L RNA and treated with DNase I (Thermo Fisher Scientific). The treated RNA was reverse transcribed into single-stranded cDNA using a High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific) and stored at -20&#xb0;C.</p>
</sec>
<sec id="s2_6">
<label>2.6</label>
<title>Gene expression analyses</title>
<sec id="s2_6_1">
<label>2.6.1</label>
<title>Digital PCR</title>
<p>Digital PCR (dPCR) was performed using a QIAcuity instrument (QIAGEN). Reactions were prepared using a QIAcuity Probe PCR Kit (QIAGEN) in a volume of 40 &#x3bc;L. Gene expression experiments were performed in duplicate. The expression of the target gene <italic>TLR10</italic> (Hs01935337_s1) and the reference gene <italic>TOP1</italic> (Hs00243257) was measured using TaqMan Gene Expression Assays (Thermo Fisher Scientific). Reactions using TaqMan probes at a final concentration of 0.8 &#xb5;M were loaded onto a 26k nanoparticle dPCR nanoplate (QIAcuity) and performed as follows: 2 min, 95&#xb0;C, 40&#xd7; (15 s at 95&#xb0;C, 15 s at 60&#xb0;C). QIAcuity analysis software (QIAGEN) was used to analyze the results. Poisson distribution was used to calculate the number of copies of the target molecule per positive partition. To normalize the data, the copies/unit RNA of the target gene were multiplied by the normalization factor (geometric mean of TOP1), and the final data were displayed as normalized copies/unit RNA.</p>
</sec>
<sec id="s2_6_2">
<label>2.6.2</label>
<title>Pathway-focused gene expression profiling with qPCR arrays</title>
<p>The cDNA was mixed with PowerUp&#x2122; SYBR<sup>&#xae;</sup> Green Master Mix (Applied Biosystems) and aliquoted into the wells of a pre-made qPCR profiling array (RT<sup>2</sup> Profiler PCR Array, GeneGlobe ID-PAHS-018Z, Qiagen) containing a panel of 84 genes associated with the TLR signaling pathway. Amplification results were normalized to the five housekeeping genes <italic>ACTB</italic>, <italic>B2M</italic>, <italic>GAPDH</italic>, <italic>HPRT1</italic>, and <italic>RPLP0</italic>. Fold changes in gene expression between immunostimulated A549<sub>C</sub> and immunostimulated A549-TLR10<sub>OE</sub> cells were calculated using the 2<sup>&#x2212;&#x394;&#x394;CT</sup> method (<xref ref-type="bibr" rid="B24">24</xref>).</p>
</sec>
<sec id="s2_6_3">
<label>2.6.3</label>
<title>Reverse transcription quantitative PCR</title>
<p>Further expression analyses were performed for individual genes identified as differentially expressed during qPCR array screening and/or consistently associated with the SARS-CoV-2 immune response in the literature. Primers were designed for the genes of interest using the online tool PrimerBlast (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi">https://www.ncbi.nlm.nih.gov/tools/primer-blast/index.cgi</ext-link> (accessed May 27, 2023) (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S1</bold>
</xref>). All the reactions were performed in triplicate. Thermal cycling conditions were as follows: 10 min at 95&#xb0;C, 40 cycles at 95&#xb0;C for 15 s and at 60&#xb0;C for 1 min. Primer efficiencies were determined for all the primer pairs using a six-log cDNA dilution range. All the determined primer pair efficiencies were in the range of 100 &#xb1; 10% and the R<sup>2</sup> &#x2265; 0.99. Relative differential expression between immunostimulated A549<sub>C</sub> and immunostimulated A549-TLR10<sub>OE</sub> cells was calculated using the 2<sup>-&#x394;&#x394;Ct</sup> method (<xref ref-type="bibr" rid="B24">24</xref>). A gene was considered differentially expressed if it showed at least a two-fold change.</p>
</sec>
</sec>
<sec id="s2_7">
<label>2.7</label>
<title>ELISA cytokine assays</title>
<p>The cell culture medium of A549 and THP-1 cells was removed four and 24 hours after incubation with SARS-CoV-2 proteins S and N, respectively, and centrifuged at 1000 &#xd7; g for 10 minutes at 4&#xb0;C. The concentrations of IL8 (assay range: 15.6-1,000 pg/mL, BMS204-3INST, Thermo Fisher Scientific), IL1&#x3b2; (assay range: 7.8-500 pg/mL, BMS224INST, Thermo Fisher Scientific), CXCL10 (assay range: 3.1-200 pg/mL, BMS284INST, Thermo Fisher Scientific), IFN&#x3b2; (assay range: 50-4000 pg/mL, 414101, Thermo Fisher Scientific), IL10 (assay range: 50-4000 pg/mL, BMS215INST, Thermo Fisher Scientific), CCL20 (assay range: 0.8-600 pg/mL, EHCCL20, Thermo Fisher Scientific) and TNF&#x3b1; (assay range: 7.8-500 pg/mL, BMS223INST, Thermo Fisher Scientific) were measured according to the manufacturer&#x2019;s instructions.</p>
</sec>
<sec id="s2_8">
<label>2.8</label>
<title>Western blot</title>
<p>Approximately 5&#xd7;10<sup>5</sup> A549 cells were seeded in 6-well plates and transfected with plasmids to overexpress <italic>TLR10</italic> as previously described. After two days, cells were lysed in ice-cold RIPA lysis buffer supplemented with protease and phosphatase inhibitor cocktails (4906845001, Roche). Protein concentration was determined using the Pierce BCA Protein Assay Kit (# 23227, Thermo Fisher Scientific) according to the manufacturer&#x2019;s instructions. Approximately 15 &#x3bc;g of the cell lysate was transferred to a precast NuPAGE 4-12% gel (NP0321BOX, Thermo Fisher Scientific), electrophoresed at 180 V for two hours and immunoblotted onto a PVDF membrane. Membranes were stained with primary antibodies against TLR10 (1:1000) (PRS3275, Sigma&#x2013;Aldrich) and &#x3b2;-actin (1:5000) (MA1-140, Thermo Fisher Scientific). Secondary HRP-conjugated anti-rabbit antibody (1:5000) (31460, Thermo Fisher Scientific) and HRP-conjugated anti-mouse antibody (1:5000) (31430, Thermo Fisher Scientific) were used for visualization, and the HRP signal recorded after two hours of incubation with TrueBlue peroxidase substrate (5510-0030, LGS Diagnostics).</p>
</sec>
<sec id="s2_9">
<label>2.9</label>
<title>Statistical analysis</title>
<p>Data were analyzed using Prism 8 version 10.2.2 software (GraphPad). Statistical significance was determined using a two-tailed, unpaired Student&#x2019;s t-test (p &#x2264; 0.05 was considered statistically significant).</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<p>Overexpression of endogenous <italic>TLR10</italic> in immunostimulated A549 cells significantly altered the expression of several cytokines and genes associated with TLR signaling. Furthermore, overexpression of <italic>TLR10</italic> in A549 cells co-cultured with THP-1 cells altered the expression of genes in THP-1 cells.</p>
<sec id="s3_1">
<label>3.1</label>
<title>TLR10 upregulation</title>
<p>Using the CRISPR/dCas9 system, we were able to increase the expression of <italic>TLR10</italic> by approximately 24-fold (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref>). The induction appears to translate to the protein level, which is visible in the Western blot (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>; <xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S1</bold>
</xref>). After overexpression, TLR10 was mainly localized at the cell membrane, but to a lesser extent also in the cytoplasm (possibly in endosomes) (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figure S2</bold>
</xref>). Supplementation of the growth medium with calcitriol (active form of vitamin D) significantly affected <italic>TLR10</italic> expression, while supplementation with other vitamins (ascorbic acid &#x2013; vitamin C, folic acid &#x2013; vitamin B9, and riboflavin &#x2013; vitamin B2) had no statistically significant effect on the expression of <italic>TLR10</italic> at any of the concentrations used. The addition of the biologically active form of vitamin D to the growth medium at a high concentration (200 &#xb5;M) increased the expression of <italic>TLR10</italic> approximately four-fold after 24 hours of incubation and approximately 16-fold after 48 hours of incubation (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2C</bold>
</xref>).</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Differential expression of TLR10. <bold>(A)</bold> Differential expression of <italic>TLR10</italic> induced by CRISPR/dCas9, evaluated by dPCR. <bold>(B)</bold> Western blot showing TLR10 protein 48 hours after transfection. <bold>(C)</bold> Differential expression of <italic>TLR10</italic> after addition of different vitamins to the cell growth medium, evaluated by qPCR. Data are presented as mean with SEM of three independent experiments; *p &#x2264; 0.05, **p &#x2264; 0.01 by unpaired Student&#x2019;s t-test.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1490478-g002.tif"/>
</fig>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>Differential expression of immune-associated genes in A549 and THP-1 cells challenged with SARS-CoV-2 proteins S and N</title>
<p>Both S and N protein induced the expression of the proinflammatory cytokines <italic>TNF&#x3b1;</italic> and <italic>IL1&#x3b2;</italic> and the chemokines <italic>CXCL10</italic> and <italic>IL8</italic>, while <italic>IFN&#x3b2;</italic> was downregulated in A549 cells (p &gt; 0.05). In general, N protein induced the relative expression of inflammatory mediators in A549 cells earlier than S protein as shown by the expression data for four- and 24-hour time points after immunostimulation (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). The highest differential expression in immunostimulated A549 cells was observed for <italic>IL8</italic> and <italic>CXCL10</italic>, for both virulence factors, and for <italic>TNF&#x3b1;</italic> in the case of N protein challenge after four hours (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3A</bold>
</xref>). The induction of inflammatory mediators in THP-1 cells was weaker than in A549 cells. The S protein increased the expression of <italic>TNF&#x3b1;</italic>, <italic>IL8</italic> and <italic>IL1&#x3b2;</italic> at both time points after stimulation, while N protein induced the expression of these markers only in the &#x201c;early&#x201d; phase of immune stimulation (after four hours) (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3B</bold>
</xref>). No statistically significant difference in <italic>IFN&#x3b2;</italic> expression was observed after immunostimulation with the S or N protein.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>The S and N proteins of SARS-CoV-2 induce the differential expression of inflammatory markers (cytokines) in A549 and THP-1 cells. A549 cells <bold>(A)</bold> and THP-1 cells <bold>(B)</bold> were stimulated with the SARS-CoV-2 protein S (red) or N (blue) (both 500 ng/mL) for four and 24 hours. Gene expression of <italic>TNF&#x3b1;</italic>, <italic>IL8</italic>, <italic>CXCL10</italic>, <italic>IL1&#x3b2;</italic> and <italic>IFN&#x3b2;</italic> was measured by RT&#x2013;qPCR and compared between immunostimulated and untreated cells. Data are presented as mean with SEM of three independent experiments; *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001 according to unpaired Student&#x2019;s t tests.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1490478-g003.tif"/>
</fig>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>Immunomodulatory effects of TLR10 overexpression in A549 cells immunostimulated with SARS-CoV-2 S protein</title>
<p>Using a qPCR array focusing on genes associated with the TLR signaling pathway, we investigated the differential expression of 84 genes involved in this pathway. We compared the expression of the genes in immunostimulated cells overexpressing <italic>TLR10</italic> (A549-TLR10<sub>OE</sub>) with immunostimulated cells with native <italic>TLR10</italic> expression (A549<sub>C</sub>) (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S2</bold>
</xref>; <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4A</bold>
</xref>). Gene expression analysis revealed five upregulated (<italic>NFRK&#x3b2;, TBK1, TLR10, NFK&#x3b2;IL1, IRAK1</italic>) and 13 downregulated (<italic>CSF3, IL6, CXCL10, IFN&#x3b2;1, CSF2, IL1&#x3b2;, TNF&#x3b1;, CLE4E, IFN&#x3b1;, CCL2, NFK&#x3b2;IA, IL1A, TLR3</italic>) genes four hours after stimulation with the S protein (&#x2265; 2-fold change and a p-value &#x2264; 0.05 was used as a threshold for differential expression). Prominent immune mediators such as <italic>IL6</italic>, <italic>CXCL10</italic>, <italic>IL1&#x3b2;</italic>, <italic>TNF&#x3b1;</italic>, <italic>IFN&#x3b2;</italic> and the colony-stimulating factors <italic>CSF2</italic> and <italic>CSF</italic>3 were downregulated, while genes encoding adaptor proteins, kinases and transcription factors such as <italic>IRAK1</italic>, <italic>TBK1</italic>, <italic>FOS</italic> and <italic>ELK</italic> were upregulated in response to <italic>TLR10</italic> overexpression. Twenty-four hours after stimulation, the effect of <italic>TLR10</italic> overexpression diminished, as only three genes were downregulated (<italic>IL6</italic>, <italic>CSF3</italic> and <italic>IRAK2</italic>).</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Differential expression of immune-associated genes in A549-TLR10<sub>OE</sub> cells challenged with the S protein. <bold>(A)</bold> a volcano plot of differential expression between immunostimulated A549-TLR10<sub>OE</sub> and immunostimulated A549<sub>C</sub> cells challenged for four and 24 hours as determined by qPCR arrays. Log2-fold changes are plotted against the p-values of the t-test. Significantly downregulated genes are marked as orange dots, while significantly upregulated genes are marked as red dots. Fold-change (&#x2265; 2-fold, vertical lines) and statistically significant difference (p &#x2264; 0.05, horizontal line) were used as threshold for differential expression. <bold>(B)</bold> Cytokine secretion was measured by ELISA. Data are presented as mean with SEM of three independent experiments; *p &#x2264; 0.05, **p &#x2264; 0.01 by unpaired Student&#x2019;s t-test. OE, overexpressed; C, control.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1490478-g004.tif"/>
</fig>
<p>To further investigate the effects of <italic>TLR10</italic> overexpression, protein concentrations of known inflammatory markers, namely, IL8, CXCL10, IFN&#x3b2;, TNF&#x3b1;, CCL20, and IL1&#x3b2;, were measured by ELISA (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4B</bold>
</xref>). The concentrations of the cytokines in the medium were not entirely consistent with the qPCR results, e.g. TNF&#x3b1; levels were not significantly different between the treatment and the control, while IL8 levels were elevated in the sample overexpressing <italic>TLR10</italic> at four hours after immunostimulation. Additionally, we were unable to detect IL1&#x3b2; in the growth medium, while the measured IFN&#x3b2; levels were below the range value of the assay (50 pg/mL).</p>
</sec>
<sec id="s3_4">
<label>3.4</label>
<title>Immunomodulatory effects of TLR10 overexpression in A549 cells immunostimulated with SARS-CoV-2 N protein</title>
<p>A similar response to immunostimulation with S protein was observed after immunostimulation with N protein (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table S2</bold>
</xref>; <xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5A</bold>
</xref>). After four hours, 12 genes were downregulated (<italic>CD180, CXCL10, CSF2, CD180, LTA, IFN&#x3b2;1, TNF&#x3b1;, BTK, FOS, IL6, NFKBIA, TLR2</italic>), and five were upregulated (<italic>CD14, TLR10, TBK1, IRAK1, MAP2K3</italic>) in response to <italic>TLR10</italic> overexpression. After 24 hours, the effect of <italic>TLR10</italic> overexpression diminished, as only four genes were downregulated (<italic>IL1&#x3b2;, CLE4E, CD86</italic>, and <italic>CD80</italic>) and four were upregulated (<italic>CSF2, CSF3</italic>, and <italic>IFN&#x3b2;1</italic>). Cytokine secretion was measured by ELISA for IL8, CXCL10, IFN&#x3b2;, and TNF&#x3b1;, CCL20, and IL1&#x3b2; (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5B</bold>
</xref>). The concentrations of cytokines in the medium were not entirely consistent with the qPCR results, for example concentrations of TNF&#x3b1; were not significantly different between treatment and control, while CCL20 levels were elevated in the sample overexpressing <italic>TLR10</italic> 24 hours after immunostimulation. We were unable to detect IL1&#x3b2; in the growth medium, while the measured IFN&#x3b2; levels were below the range value of the assay (50 pg/mL).</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Differential expression of immune-associated genes in A549-TLR10<sub>OE</sub> challenged with the N protein. <bold>(A)</bold> a volcano plot of differential expression between immunostimulated A549-TLR10<sub>OE</sub> and immunostimulated A549<sub>C</sub> cells challenged for four and 24 hours as determined by qPCR arrays. Log<sub>2-</sub>fold changes are plotted against the p-values of the t-test. Significantly downregulated genes are marked as light blue dots, while significantly upregulated genes are marked as dark blue dots. Fold-change (&#x2265; 2-fold, vertical lines) and statistically significant difference (p &#x2264; 0.05, horizontal line) were used as threshold for differential expression. <bold>(B)</bold> Cytokine secretion was measured by ELISA. Data are presented as mean with SEM of three independent experiments; **p &#x2264; 0.01 by unpaired Student&#x2019;s t-test. OE, overexpressed; C, control.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1490478-g005.tif"/>
</fig>
</sec>
<sec id="s3_5">
<label>3.5</label>
<title>TLR10 overexpression in immunostimulated A549 cells modulates gene expression of THP-1 monocytes in co-culture</title>
<p>In the co-culture experiment, we investigated whether overexpression of <italic>TLR10</italic> in immunostimulated A549 cells affects gene expression in the monocytic human leukemia cell line THP-1. The results showed that overexpression of <italic>TLR10</italic> in immunostimulated A549-TLR10<sub>OE</sub> altered expression of genes in co-cultured THP-1, by downregulating expression of various proinflammatory cytokines (<italic>TNF&#x3b1;</italic>, <italic>IL8</italic>, <italic>CXCL10</italic>, and <italic>IL1&#x3b2;</italic>) four and 24 hours after immunostimulation with N protein and after four hours in the case of S protein, while their expression was upregulated 24 hours after immunostimulation with S protein (<xref ref-type="fig" rid="f6">
<bold>Figures&#xa0;6A, C</bold>
</xref>). In response to <italic>TLR10</italic> overexpression in immunostimulated A549 cells, granulocyte-macrophage colony-stimulating factors 2 (<italic>CSF2</italic>) and <italic>CSF3</italic>, which activate monocytes to produce inflammatory cytokines, were downregulated in A549-TLR10<sub>OE</sub> (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4A</bold>
</xref>, <xref ref-type="fig" rid="f5">
<bold>5A</bold>
</xref>) and in A549-TLR10<sub>OE</sub> co-cultured with THP-1.</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Differential expression of immune-associated genes in THP-1 cells co-cultured with immunostimulated A549-TLR10<sub>OE</sub> or immunostimulated A549<sub>C</sub> cells (A549 cells were challenged with the N or S protein for four and 24 h). <bold>(A, C)</bold> The differential expression of <italic>TNF&#x3b1;</italic>, <italic>IL8</italic>, <italic>CXCL10</italic>, <italic>IL10</italic> and <italic>IL1&#x3b2;</italic> in THP-1 cells between coculture with immunostimulated A549-TLR10<sub>OE</sub> and immunostimulated A549<sub>C</sub> cells. <bold>(B, D)</bold> The protein concentrations of TNF&#x3b1;, CXCL10, IL10, IL1&#x3b2;, and IL8 in the co-culture medium measured by ELISA. Data are presented as mean with SEM of three independent; *p &#x2264; 0.05, **p &#x2264; 0.01 by unpaired Student&#x2019;s t-test. OE, overexpressed; C, control.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-15-1490478-g006.tif"/>
</fig>
<p>The overexpression of <italic>TLR10</italic> affected the concentrations of cytokines in the co-culture medium (<xref ref-type="fig" rid="f6">
<bold>Figures&#xa0;6B, D</bold>
</xref>). In the case of immunostimulation with S protein (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6B</bold>
</xref>), the concentrations of IL8 (concentrations in some samples exceeded recommended assay range value of 1000 pg/mL), IL1&#x3b2; and CXCL10 were lower in the case of <italic>TLR10</italic> overexpression at both time- points after immunostimulation, while the concentrations of IL10 and TNF&#x3b1; were higher 24 hours after immunostimulation and undetectable four hours after stimulation. In the case of four-hour immunostimulation with N protein, the concentrations of the cytokines CXCL10 and IL1&#x3b2; were higher in the A549-TLR10<sub>OE</sub> co-culture medium than in the A549<sub>C</sub> co-culture medium. However, 24 hours after immunostimulation the levels of all the cytokines were lower in the A549-TLR10<sub>OE</sub> co-culture medium (significantly in case of CXCL10). The concentrations of TNF&#x3b1; and IL10 were lower in the A549-TLR10<sub>OE</sub> co-culture medium than in the A549<sub>C</sub> co-culture medium at both time points after immunostimulation with N protein (p &gt; 0.05), but the measured levels of IL10 and TNF&#x3b1; (in some of the samples) were below the recommended range values for the assays (7.8 pg/mL for TNF&#x3b1; and 50 pg/mL for IL10).</p>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>Although studies have shown that some TLRs recognize SARS-CoV-2 and trigger an inflammatory response, the role of TLR10 in SARS-CoV-2 infection has not yet been investigated. TLR10 is considered an orphan receptor without a clear function, a specific ligand or a specific mode of action (<xref ref-type="bibr" rid="B16">16</xref>). Since mice lack a functional TLR10 receptor (<xref ref-type="bibr" rid="B25">25</xref>), studies on TLR10 have mainly been conducted <italic>in vitro</italic> and have yielded contradictory results. Depending on cell type, ligand, expression type and dimerization (homo or heterodimers), TLR10 has been associated with either a proinflammatory (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B27">27</xref>) or an anti-inflammatory function (<xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>). TLR10 forms heterodimers with the TLR2 subfamily; TLR10-TLR1/TLR6 dimers have been shown to have proinflammatory effects (<xref ref-type="bibr" rid="B30">30</xref>), while TLR10-TLR2 dimers have been associated with anti-inflammatory effects (<xref ref-type="bibr" rid="B25">25</xref>). Recent studies have shown that TLR10 is involved in triggering the innate immune response against viruses by recognizing dsRNA (<xref ref-type="bibr" rid="B31">31</xref>) as well as viral proteins such as HIV-1 (<xref ref-type="bibr" rid="B32">32</xref>) and influenza virus proteins (<xref ref-type="bibr" rid="B33">33</xref>). A study by Zheng et&#xa0;al. (<xref ref-type="bibr" rid="B14">14</xref>) showed that TLR2 and MyD88 are required for the inflammatory response induced by &#x3b2;-coronaviruses (<xref ref-type="bibr" rid="B14">14</xref>). Therefore, we hypothesized that TLR10 may be involved in immune signaling in response to certain SARS-CoV-2 structural proteins, possibly through heterodimerization with TLR2.</p>
<p>To investigate the potential role of TLR10 in the inflammatory response induced by SARS-CoV-2 proteins in lung epithelial cells, we overexpressed endogenous <italic>TLR10</italic> in A549 cells and immunostimulated the cells with SARS-CoV-2 S or N protein. In addition to CRISPR-induced activation (CRISPRa) we were able to successfully induce expression of endogenous <italic>TLR10</italic> by supplementing the growth medium of challenged A549 cells with an active form of vitamin D. It is known that the active form of vitamin D interacts with the nuclear vitamin D receptor (VDR). VDR then forms a heterodimer with retinoid-X-receptor alpha (RXR-&#x3b1;) and the complex can bind to the vitamin D response elements located in the promoter regions of the target genes. Three potential VDR binding sites have been identified within the proximal promoter of <italic>TLR10</italic>, located within 250 base pairs upstream of the transcription start site (<xref ref-type="bibr" rid="B34">34</xref>). The interaction of vitamin D with TLR10 could potentially influence the body&#x2019;s defense mechanisms against viral infections, including SARS-CoV-2. Further research is needed to fully understand the effects of this signaling pathway in the context of COVID-19 and other viral infections.</p>
<p>Studies on serum cytokines in patients with COVID-19 have shown that the concentrations of many cytokines and chemokines, such as IL6, TNF&#x3b1;, CSFs, monocyte chemoattractant proteins (MCPs) and CXCL10 (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B35">35</xref>), are elevated in response to SARS-CoV-2 infection and correlate positively with the severity of the disease (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>). Therefore, downregulation of the aforementioned markers could alleviate the symptoms of COVID-19 and prevent hyperinflammation. First, we investigated whether the S or N protein triggers inflammatory signaling pathways and cytokine production in A549 cells. We found that the presence of S or N protein in the medium caused differential expression of inflammatory genes. Next, we investigated whether the expression level of <italic>TLR10</italic> affects the expression of inflammatory mediators in immunostimulated A549 cells. We found that overexpression of <italic>TLR10</italic> downregulates the expression of several proinflammatory cytokines. The genes that were significantly (p &lt; 0.05) downregulated in both cases (after stimulation with the S or N protein) at least one time-point after immunostimulation (four or 24 hours after immunostimulation) were <italic>IL6</italic>, <italic>CXCL10</italic>, <italic>TNF&#x3b1;</italic>, <italic>IFN&#x3b2;</italic>, <italic>CSF2</italic>, and <italic>NFKBIA</italic>, while the only upregulated gene in both cases was <italic>TBK1</italic>.</p>
<p>The vast majority of inflammatory cells that infiltrate the lungs after infection are monocytes and macrophages (<xref ref-type="bibr" rid="B38">38</xref>, <xref ref-type="bibr" rid="B39">39</xref>). Angiotensin converting enzyme 2 (ACE2), through which SARS CoV-2 enters target cells, is only weakly expressed in monocytes (<xref ref-type="bibr" rid="B40">40</xref>), and the signal for their activation during SARS-CoV-2 infections is thought to originate from paracrine signaling of infected tissue. Several known molecules involved in monocyte migration are TNF&#x3b1;, CCL2, IL1&#x3b2;, IL8, and CSFs (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>). The co-culture experiments with immunostimulated A549 and monocytic THP-1 cells were performed to investigate the effects of <italic>TLR10</italic> overexpression in the immunostimulated epithelial A549 cell line on TLR pathway-associated gene expression of immune cells (THP-1) in a co-culture cell model. Cell co-cultures contribute to a better understanding of complex biological processes, as a variety of signaling pathways and mechanisms require direct interactions between cells, including paracrine signaling through cytokines, growth factors, and transcriptional regulators that are activated or repressed in response to pathogens (<xref ref-type="bibr" rid="B43">43</xref>). Our results suggest that overexpression of <italic>TLR10</italic> in A549 epithelial cells influences cytokine and chemokine expression in co-cultured THP-1 cells. The response of THP-1 cells to <italic>TLR10</italic> overexpression in co-cultured A549 cells immunostimulated with S or N protein (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6</bold>
</xref>) was downregulation of several proinflammatory cytokines, consistent with previous reports (<xref ref-type="bibr" rid="B12">12</xref>). However, when the co-cultures were immunostimulated with S protein, we found that some of the cytokines (<italic>IL8</italic>, <italic>CXCL10</italic>, <italic>IFN&#x3b2;</italic>, <italic>TNF&#x3b1;</italic>) in the THP-1 cells were initially downregulated in the &#x201c;early&#x201d; phase (4 hours) after immunostimulation and upregulated in the &#x201c;late&#x201d; phase (24 hours), but the concentrations of all measured cytokines (except of TNF&#x3b1;) were lower in A549-TLR<sub>OE</sub> co-cultures than in A549<sub>C</sub> co-cultures 24 hours after immunostimulation (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6B</bold>
</xref>). Furthermore, S protein immunostimulation of A549-TLR10<sub>OE</sub> cells co-cultured with THP-1 led to a significant upregulation of the anti-inflammatory cytokine <italic>IL10</italic> in THP-1 cells. When N protein immunostimulated A549-TLR10<sub>OE</sub> and THP-1 cells were co-cultured, the expression of inflammatory genes such as <italic>IL8</italic>, <italic>CXCL10</italic>, and <italic>IL1&#x3b2;</italic> was downregulated in THP-1 cells after 4 hours compared to A549<sub>C</sub> co-cultures (<xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6C</bold>
</xref>), but the cytokine concentrations in the medium were not downregulated until 24 hours. Such reduced correlations between mRNA expression and protein levels could be explained by transcriptional delays &#x2013; the time when transcription starts and when protein is formed (<xref ref-type="bibr" rid="B44">44</xref>, <xref ref-type="bibr" rid="B45">45</xref>), which is why transcriptional regulation may not be immediately visible at the protein level.</p>
<p>In the present study, we demonstrated that TLR10 is able to modulate the immune response to SARS-CoV-2 proteins S and N in A549 and THP-1 cells. In general, we observed a downregulation of inflammatory cytokines when <italic>TLR10</italic> was overexpressed in immunostimulated A549 cells. However, some contradictory results (e.g. upregulation of some proinflammatory cytokines in immunostimulated A549-TLR10<sub>OE</sub> cells compared to immunostimulated A549<sub>C</sub> cells) and discrepancies between the transcriptional regulation of some genes and their protein levels were observed, especially in the &#xbb;early&#xab; phase after immunostimulation, which may indicate that the mechanisms of TLR10 functions are complex and depend on virulence factor, incubation time, cell type, and TLR10 concentration. Furthermore, such discrepancies could be caused by the kinetics of CRISPRa regulation, as overexpression is not stable but decreases over time, as well as by possible epigenetic effects acting on RNA-mediated processes and preventing or delaying translation. In addition, we were unable to detect IL1&#x3b2; in A549 medium by ELISA or to optimize the dilutions of some of the samples so that their levels would fall within the recommended assay range (e.g. the measured IL10 concentrations in co-culture medium was below the recommended assay range value).</p>
<p>Our results suggest that TLR10 may mediate the extent of inflammation induced by SARS-CoV-2 by downregulating the release of inflammatory cytokines and chemokines such as CXCL10, IL6, IL8, and IFN&#x3b2;. Whether the immunosuppressive effect of TLR10 on epithelial cells is desirable in patients with severe COVID-19 needs to be investigated in further experiments, as overexpression of <italic>TLR10</italic> also leads to downregulation of <italic>IFN&#x3b2;</italic>, a key component of the antiviral response that is already suppressed by the elusive mechanism of SARS-CoV-2 (<xref ref-type="bibr" rid="B46">46</xref>). Delayed type-I interferon signaling promotes the accumulation of proinflammatory cytokines and chemokines, which may worsen the prognosis of patients. However, we believe that the immunomodulatory effects of TLR10 may represent an opportunity for intervention approaches to rebalance the excessive immune response at a later stage of infection, when an excess of inflammatory cytokines can become harmful to the tissue (cytokine storm).</p>
<p>Further studies are needed to determine the TLR10 ligands, to explain the mode of action by which it exerts immunomodulatory functions, and to determine the expression kinetics of target genes when CRISPRa is used. The lung is an organ suitable for drug delivery in aerosolized form by inhalation. Recent advances in inhalation strategies (<xref ref-type="bibr" rid="B47">47</xref>) may enable the development of inhalable liquid or powder CRISPR-based formulations for therapies and, in perspective, lead to the development of novel treatment strategies that utilize the immunomodulatory functions of TLR10.</p>
</sec>
</body>
<back>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material</bold>
</xref>.</p>
</sec>
<sec id="s6" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>Ethical approval was not required for the studies on humans in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used. Ethical approval was not required for the studies on animals in accordance with the local legislation and institutional requirements because only commercially available established cell lines were used.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>&#x160;K: Formal analysis, Investigation, Methodology, Project administration, Validation, Visualization, Writing &#x2013; original draft. MN: Conceptualization, Formal analysis, Funding acquisition, Methodology, Resources, Supervision, Writing &#x2013; review &amp; editing. JO: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Resources, Supervision, Writing &#x2013; original draft, Writing &#x2013; review &amp; editing.</p>
</sec>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This research was supported by the Slovenian Research and Innovation Agency (ARIS) through research programme P4-0220 and Slovenian young researchers programme (&#x160;K).</p>
</sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec id="s11" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2024.1490478/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2024.1490478/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="DataSheet1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Astuti</surname> <given-names>I</given-names>
</name>
<name>
<surname>Ysrafil</surname>
</name>
</person-group>. <article-title>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): An overview of viral structure and host response</article-title>. <source>Diabetes Metab Syndrome: Clin Res Rev</source>. (<year>2020</year>) <volume>14</volume>:<page-range>407&#x2013;12</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.dsx.2020.04.020</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>J</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>M</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>X</given-names>
</name>
<name>
<surname>Montaner</surname> <given-names>LJ</given-names>
</name>
</person-group>. <article-title>Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts</article-title>. <source>J Leukoc Biol</source>. (<year>2020</year>) <volume>108</volume>:<page-range>17&#x2013;41</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/JLB.3COVR0520-272R</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hadjadj</surname> <given-names>J</given-names>
</name>
<name>
<surname>Yatim</surname> <given-names>N</given-names>
</name>
<name>
<surname>Barnabei</surname> <given-names>L</given-names>
</name>
<name>
<surname>Corneau</surname> <given-names>A</given-names>
</name>
<name>
<surname>Boussier</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients</article-title>. <source>Science</source>. (<year>2020</year>) <volume>724</volume>:<page-range>718&#x2013;24</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.abc6027</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>X</given-names>
</name>
<name>
<surname>Yin</surname> <given-names>S</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Zheng</surname> <given-names>W</given-names>
</name>
<name>
<surname>Dong</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>LPS-induced proinflammatory cytokine expression in human airway epithelial cells and macrophages via NF-&#x3ba;B, STAT3 or AP-1 activation</article-title>. <source>Mol Med Rep</source>. (<year>2018</year>) <volume>17</volume>:<page-range>5484&#x2013;91</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3892/mmr.2018.8542</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Ren</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zhao</surname> <given-names>J</given-names>
</name>
<name>
<surname>Hu</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>. <source>The Lancet</source>. (<year>2020</year>) <volume>395</volume>:<fpage>497</fpage>&#x2013;<lpage>506</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0140-6736(20)30183-5</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coperchini</surname> <given-names>F</given-names>
</name>
<name>
<surname>Chiovato</surname> <given-names>L</given-names>
</name>
<name>
<surname>Croce</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system</article-title>. <source>Frontiers in Immunology</source>. (<year>2021</year>) <volume>12</volume>:<page-range>1&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.668507</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bals</surname> <given-names>R</given-names>
</name>
<name>
<surname>Hiemstra</surname> <given-names>PS</given-names>
</name>
</person-group>. <article-title>Innate immunity in the lung: How epithelial cells fight against respiratory pathogens</article-title>. <source>Eur Respir J</source>. (<year>2004</year>) <volume>23</volume>:<page-range>327&#x2013;33</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1183/09031936.03.00098803</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Onofrio</surname> <given-names>L</given-names>
</name>
<name>
<surname>Caraglia</surname> <given-names>M</given-names>
</name>
<name>
<surname>Facchini</surname> <given-names>G</given-names>
</name>
<name>
<surname>Margherita</surname> <given-names>V</given-names>
</name>
<name>
<surname>Placido</surname> <given-names>S</given-names>
</name>
<name>
<surname>Buonerba</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Toll-like receptors and COVID-19: A two-faced story with an exciting ending</article-title>. <source>Future Sci OA</source>. (<year>2020</year>) <volume>6</volume>:<page-range>10&#x2013;3</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1410293111</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poulas</surname> <given-names>K</given-names>
</name>
<name>
<surname>Farsalinos</surname> <given-names>K</given-names>
</name>
<name>
<surname>Zanidis</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Activation of TLR7 and innate immunity as an efficient method against COVID-19 pandemic: imiquimod as a potential therapy</article-title>. <source>Nat Rev Immunol</source>. (<year>2020</year>) <volume>13</volume>:<page-range>875&#x2013;87</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri3547</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frank</surname> <given-names>MG</given-names>
</name>
<name>
<surname>Wallach</surname> <given-names>T</given-names>
</name>
<name>
<surname>Raden</surname> <given-names>M</given-names>
</name>
<name>
<surname>Hinkelmann</surname> <given-names>L</given-names>
</name>
<name>
<surname>Brehm</surname> <given-names>M</given-names>
</name>
<name>
<surname>Rabsch</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Distinct SARS-CoV-2 RNA fragments activate Toll-like receptors 7 and 8 and induce cytokine release from human macrophages and microglia</article-title>. <source>Frontiers Immunol</source>. (<year>2023</year>) <volume>13</volume>:<fpage>1</fpage>&#x2013;<lpage>14</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.1066456</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>IH</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>JW</given-names>
</name>
<name>
<surname>Kong</surname> <given-names>SW</given-names>
</name>
</person-group>. <article-title>A survey of genetic variants in SARS-CoV-2 interacting domains of ACE2, TMPRSS2 and TLR3/7/8 across populations</article-title>. <source>Infection, Genetics and Evolution</source>. (<year>2020</year>) <volume>85</volume> (<issue>5</issue>):<elocation-id>104507</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.meegid.2020.104507</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Shafiei</surname> <given-names>MS</given-names>
</name>
<name>
<surname>Longoria</surname> <given-names>C</given-names>
</name>
<name>
<surname>Schoggins</surname> <given-names>JW</given-names>
</name>
<name>
<surname>Savani</surname> <given-names>RC</given-names>
</name>
<name>
<surname>Zaki</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-&#x3ba;B pathway</article-title>. <source>ELife</source>. (<year>2021</year>) <volume>10</volume>:<fpage>1</fpage>&#x2013;<lpage>26</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.7554/eLife.68563</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aboudounya</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Heads</surname> <given-names>RJ</given-names>
</name>
</person-group>. <article-title>COVID-19 and toll-like receptor 4 (TLR4): SARS-coV-2 may bind and activate TLR4 to increase ACE2 expression, facilitating entry and causing hyperinflammation</article-title>. <source>Mediators of Inflammation</source>. (<year>2021</year>) <volume>14</volume>:<elocation-id>8874339</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2021/8874339</pub-id>
</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname> <given-names>M</given-names>
</name>
<name>
<surname>Karki</surname> <given-names>R</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>EP</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Fitzpatrick</surname> <given-names>E</given-names>
</name>
<name>
<surname>Vogel</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines</article-title>. <source>Nat Immunol</source>. (<year>2021</year>) <volume>22</volume>:<page-range>829&#x2013;38</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41590-021-00937-x</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haystead</surname> <given-names>T</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>E</given-names>
</name>
<name>
<surname>Cho</surname> <given-names>K</given-names>
</name>
<name>
<surname>Gullickson</surname> <given-names>G</given-names>
</name>
<name>
<surname>Hughes</surname> <given-names>P</given-names>
</name>
<name>
<surname>Krafsur</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Investigation of SARS-CoV-2 individual proteins reveals the <italic>in vitro</italic> and <italic>in vivo</italic> immunogenicity of membrane protein</article-title>. <source>Sci Rep</source>. (<year>2023</year>) <volume>13</volume>:<fpage>1</fpage>&#x2013;<lpage>11</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41598-023-49077-2</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fore</surname> <given-names>F</given-names>
</name>
<name>
<surname>Indriputri</surname> <given-names>C</given-names>
</name>
<name>
<surname>Mamutse</surname> <given-names>J</given-names>
</name>
<name>
<surname>Nugraha</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>TLR10 and its unique anti-inflammatory properties and potential use as a target in therapeutics</article-title>. <source>Immune Network</source>. (<year>2020</year>) <volume>20</volume>:<fpage>1</fpage>&#x2013;<lpage>10</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.4110/in.2020.20.e21</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sha</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Truong-Tran</surname> <given-names>AQ</given-names>
</name>
<name>
<surname>Plitt</surname> <given-names>JR</given-names>
</name>
<name>
<surname>Beck</surname> <given-names>LA</given-names>
</name>
<name>
<surname>Schleimer</surname> <given-names>RP</given-names>
</name>
</person-group>. <article-title>Activation of airway epithelial cells by toll-like receptor agonists</article-title>. <source>Am J Respir Cell Mol Biol</source>. (<year>2004</year>) <volume>31</volume>:<page-range>358&#x2013;64</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1165/rcmb.2003-0388OC</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knez</surname> <given-names>&#x160;</given-names>
</name>
<name>
<surname>Narat</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ogorevc</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Differential gene expression induced by different TLR agonists in A549 lung epithelial cells is modulated by CRISPR activation of TLR10</article-title>. <source>Biomolecules</source>. (<year>2023</year>) <volume>13</volume>(<issue>1</issue>):<fpage>19</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/biom13010019</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verma</surname> <given-names>R</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>JY</given-names>
</name>
</person-group>. <article-title>1,25-dihydroxyvitamin D3 facilitates M2 polarization and upregulates TLR10 expression on human microglial cells</article-title>. <source>Neuroimmunomodulation</source>. (<year>2016</year>) <volume>23</volume> (<issue>2</issue>):<page-range>75&#x2013;80</page-range>.</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sinopoli</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sciurti</surname> <given-names>A</given-names>
</name>
<name>
<surname>Isonne</surname> <given-names>C</given-names>
</name>
<name>
<surname>Santoro</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Baccolini</surname> <given-names>V</given-names>
</name>
</person-group>. <article-title>The efficacy of multivitamin, vitamin A, vitamin B, vitamin C, and vitamin D supplements in the prevention and management of COVID-19 and long-COVID: an updated systematic review and meta-analysis of randomized clinical trials</article-title>. <source>Nutrients</source>. (<year>2024</year>) <volume>16</volume>(<issue>9</issue>):<elocation-id>1345</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/nu16091345</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Majidi</surname> <given-names>N</given-names>
</name>
<name>
<surname>Rabbani</surname> <given-names>F</given-names>
</name>
<name>
<surname>Gholami</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gholamalizadeh</surname> <given-names>M</given-names>
</name>
<name>
<surname>BourBour</surname> <given-names>F</given-names>
</name>
<name>
<surname>Rastgoo</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>The effect of vitamin C on pathological parameters and survival duration of critically ill coronavirus disease 2019 patients: A randomized clinical trial</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>717816</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.717816</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>K&#xfc;mmel</surname> <given-names>LS</given-names>
</name>
<name>
<surname>Krumbein</surname> <given-names>H</given-names>
</name>
<name>
<surname>Fragkou</surname> <given-names>PC</given-names>
</name>
<name>
<surname>H&#xfc;nerbein</surname> <given-names>BL</given-names>
</name>
<name>
<surname>Reiter</surname> <given-names>R</given-names>
</name>
<name>
<surname>Papathanasiou</surname> <given-names>KA</given-names>
</name>
<etal/>
</person-group>. <article-title>Vitamin D supplementation for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>1023903</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.1023903</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chavez</surname> <given-names>A</given-names>
</name>
<name>
<surname>Wiegand</surname> <given-names>DJ</given-names>
</name>
<name>
<surname>Ter-ovanesyan</surname> <given-names>D</given-names>
</name>
<name>
<surname>Braff</surname> <given-names>JL</given-names>
</name>
<name>
<surname>Davidsohn</surname> <given-names>N</given-names>
</name>
</person-group>. <article-title>Highly-efficient Cas9-mediated transcriptional programming</article-title>. <source>Nature</source>. (<year>2015</year>) <volume>12</volume> (<issue>4</issue>):<page-range>326&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nmeth.3312</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Livak</surname> <given-names>KJ</given-names>
</name>
<name>
<surname>Schmittgen</surname> <given-names>TD</given-names>
</name>
</person-group>. <article-title>Analysis of relative gene expression data using real-time quantitative PCR and the 2-&#x394;&#x394;CT method</article-title>. <source>Methods</source>. (<year>2001</year>) <volume>25</volume>:<page-range>402&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1006/meth.2001.1262</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ranoa</surname> <given-names>DRE</given-names>
</name>
<name>
<surname>Jiang</surname> <given-names>S</given-names>
</name>
<name>
<surname>Mutha</surname> <given-names>SK</given-names>
</name>
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Baudry</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Human TLRs 10 and 1 share common mechanisms of innate immune sensing but not signaling</article-title>. <source>J Immunol</source>. (<year>2010</year>) <volume>184</volume>:<page-range>5094&#x2013;103</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.0901888</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Regan</surname> <given-names>T</given-names>
</name>
<name>
<surname>Nally</surname> <given-names>K</given-names>
</name>
<name>
<surname>Carmody</surname> <given-names>R</given-names>
</name>
<name>
<surname>Houston</surname> <given-names>A</given-names>
</name>
<name>
<surname>Shanahan</surname> <given-names>F</given-names>
</name>
<name>
<surname>MacSharry</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Identification of TLR10 as a key mediator of the inflammatory response to <italic>listeria monocytogenes</italic> in intestinal epithelial cells and macrophages</article-title>. <source>J Immunol</source>. (<year>2013</year>) <volume>191</volume>:<page-range>6084&#x2013;92</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1203245</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hasan</surname> <given-names>U</given-names>
</name>
<name>
<surname>Chaffois</surname> <given-names>C</given-names>
</name>
<name>
<surname>Gaillard</surname> <given-names>C</given-names>
</name>
<name>
<surname>Saulnier</surname> <given-names>V</given-names>
</name>
<name>
<surname>Merck</surname> <given-names>E</given-names>
</name>
<name>
<surname>Tancredi</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Human TLR10 is a functional receptor, expressed by B cells</article-title>. <source>J Immunol</source>. (<year>2005</year>) <volume>174</volume>:<page-range>2942&#x2013;50</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.174.5.2942</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oosting</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cheng</surname> <given-names>SC</given-names>
</name>
<name>
<surname>Bolscher</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Vestering-Stenger</surname> <given-names>R</given-names>
</name>
<name>
<surname>Plantinga</surname> <given-names>TS</given-names>
</name>
<name>
<surname>Verschueren</surname> <given-names>IC</given-names>
</name>
<etal/>
</person-group>. <article-title>Human TLR10 is an anti-inflammatory pattern-recognition receptor</article-title>. <source>Proceedings of the National Academy of Sciences of the United States of America</source> (<year>2014</year>) <volume>111</volume> (<issue>42</issue>):<page-range>E4478&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1410293111</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stappers</surname> <given-names>MHT</given-names>
</name>
<name>
<surname>Oosting</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ioana</surname> <given-names>M</given-names>
</name>
<name>
<surname>Reimnitz</surname> <given-names>P</given-names>
</name>
<name>
<surname>Mouton</surname> <given-names>JW</given-names>
</name>
<name>
<surname>Netea</surname> <given-names>MG</given-names>
</name>
<etal/>
</person-group>. <article-title>Genetic variation in TLR10, an inhibitory toll-like receptor, influences susceptibility to complicated skin and skin structure infections</article-title>. <source>J Infect Dis</source>. (<year>2015</year>) <volume>212</volume>:<page-range>1491&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1093/infdis/jiv229</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hasan</surname> <given-names>UA</given-names>
</name>
<name>
<surname>Dollet</surname> <given-names>S</given-names>
</name>
<name>
<surname>Vlach</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Differential induction of gene promoter constructs by constitutively active human TLRs</article-title>. <source>Biochem Biophys Res Commun</source>. (<year>2004</year>) <volume>321</volume>:<page-range>124&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbrc.2004.06.134</pub-id>
</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>SMY</given-names>
</name>
<name>
<surname>Yip</surname> <given-names>TF</given-names>
</name>
<name>
<surname>Yan</surname> <given-names>S</given-names>
</name>
<name>
<surname>Jin</surname> <given-names>DY</given-names>
</name>
<name>
<surname>Wei</surname> <given-names>HL</given-names>
</name>
<name>
<surname>Guo</surname> <given-names>RT</given-names>
</name>
<etal/>
</person-group>. <article-title>Recognition of double-stranded RNA and regulation of interferon pathway by toll-like receptor 10</article-title>. <source>Front Immunol</source>. (<year>2018</year>) <volume>9</volume>:<elocation-id>516</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2018.00516</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Henrick</surname> <given-names>BM</given-names>
</name>
<name>
<surname>Yao</surname> <given-names>XD</given-names>
</name>
<name>
<surname>Zahoor</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Abimiku</surname> <given-names>A</given-names>
</name>
<name>
<surname>Osawe</surname> <given-names>S</given-names>
</name>
<name>
<surname>Rosenthal</surname> <given-names>KL</given-names>
</name>
</person-group>. <article-title>TLR10 senses HIV-1 proteins and significantly enhances HIV-1 infection</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<elocation-id>482</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.00482</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname> <given-names>SMY</given-names>
</name>
<name>
<surname>Kok</surname> <given-names>KH</given-names>
</name>
<name>
<surname>Jaume</surname> <given-names>M</given-names>
</name>
<name>
<surname>Cheung</surname> <given-names>TKW</given-names>
</name>
<name>
<surname>Yip</surname> <given-names>TF</given-names>
</name>
<name>
<surname>Lai</surname> <given-names>JCC</given-names>
</name>
<etal/>
</person-group>. <article-title>Toll-like receptor 10 is involved in induction of innate immune responses to influenza virus infection</article-title>. <source>Proc Natl Acad Sci United States America</source>. (<year>2014</year>) <volume>111</volume>:<page-range>3793&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1324266111</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Verma</surname> <given-names>R</given-names>
</name>
<name>
<surname>Jung</surname> <given-names>JH</given-names>
</name>
<name>
<surname>Kim</surname> <given-names>JY</given-names>
</name>
</person-group>. <article-title>1,25-Dihydroxyvitamin D3 up-regulates TLR10 while down-regulating TLR2, 4, and 5 in human monocyte THP-1</article-title>. <source>J Steroid Biochem Mol Biol</source>. (<year>2014</year>) <volume>141</volume>:<fpage>1</fpage>&#x2013;<lpage>6</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jsbmb.2013.12.012</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coperchini</surname> <given-names>F</given-names>
</name>
<name>
<surname>Chiovato</surname> <given-names>L</given-names>
</name>
<name>
<surname>Croce</surname> <given-names>L</given-names>
</name>
<name>
<surname>Magri</surname> <given-names>F</given-names>
</name>
<name>
<surname>Rotondi</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system</article-title>. <source>Cytokine Growth Factor Rev</source>. (<year>2020</year>) <volume>53</volume>:<fpage>25</fpage>&#x2013;<lpage>32</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cytogfr.2020.05.003</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mabrey</surname> <given-names>FL</given-names>
</name>
<name>
<surname>Morrell</surname> <given-names>ED</given-names>
</name>
<name>
<surname>Wurfel</surname> <given-names>MM</given-names>
</name>
</person-group>. <article-title>TLRs in COVID-19: How they drive immunopathology and the rationale for modulation</article-title>. <source>Innate Immun</source>. (<year>2021</year>) <volume>27</volume>:<page-range>503&#x2013;13</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/17534259211051364</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karki</surname> <given-names>R</given-names>
</name>
<name>
<surname>Sharma</surname> <given-names>BR</given-names>
</name>
<name>
<surname>Tuladhar</surname> <given-names>S</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>EP</given-names>
</name>
<name>
<surname>Zalduondo</surname> <given-names>L</given-names>
</name>
<name>
<surname>Samir</surname> <given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Synergism of TNF-&#x3b1; and IFN-&#x3b3; Triggers inflammatory cell death, tissue damage, and mortality in SARS-coV-2 infection and cytokine shock syndromes</article-title>. <source>Cell</source>. (<year>2021</year>) <volume>184</volume>:<fpage>149</fpage>&#x2013;<lpage>168.e17</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cell.2020.11.025</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soy</surname> <given-names>M</given-names>
</name>
<name>
<surname>Keser</surname> <given-names>G</given-names>
</name>
<name>
<surname>Atag&#xfc;nd&#xfc;z</surname> <given-names>P</given-names>
</name>
<name>
<surname>Tabak</surname> <given-names>F</given-names>
</name>
<name>
<surname>Atag&#xfc;nd&#xfc;z</surname> <given-names>I</given-names>
</name>
<name>
<surname>Kayhan</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment</article-title>. <source>Clin Rheumatol</source>. (<year>2020</year>) <volume>39</volume>:<page-range>2085&#x2013;94</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s10067-020-05190-5</pub-id>
</citation>
</ref>
<ref id="B39">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hou</surname> <given-names>F</given-names>
</name>
<name>
<surname>Xiao</surname> <given-names>K</given-names>
</name>
<name>
<surname>Tang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Diversity of macrophages in lung homeostasis and diseases</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>753940</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.753940</pub-id>
</citation>
</ref>
<ref id="B40">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ropa</surname> <given-names>J</given-names>
</name>
<name>
<surname>Cooper</surname> <given-names>S</given-names>
</name>
<name>
<surname>Capitano</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Van&#x2019;t Hof</surname> <given-names>W</given-names>
</name>
<name>
<surname>Broxmeyer</surname> <given-names>HE</given-names>
</name>
</person-group>. <article-title>Human hematopoietic stem, progenitor, and immune cells respond ex vivo to SARS-coV-2 spike protein</article-title>. <source>Stem Cell Rev Rep</source>. (<year>2021</year>) <volume>17</volume>:<page-range>253&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12015-020-10056-z</pub-id>
</citation>
</ref>
<ref id="B41">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paolini</surname> <given-names>A</given-names>
</name>
<name>
<surname>Borella</surname> <given-names>R</given-names>
</name>
<name>
<surname>Biasi</surname> <given-names>S</given-names>
</name>
<name>
<surname>Neroni</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mattioli</surname> <given-names>M</given-names>
</name>
<name>
<surname>Lo</surname> <given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Cell death in coronavirus infections: uncovering its role during COVID-19</article-title>. <source>Cells</source>. (<year>2021</year>) <volume>10</volume>(<issue>7</issue>):<elocation-id>1585</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cells10071585</pub-id>
</citation>
</ref>
<ref id="B42">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gschwandtner</surname> <given-names>M</given-names>
</name>
<name>
<surname>Derler</surname> <given-names>R</given-names>
</name>
<name>
<surname>Midwood</surname> <given-names>KS</given-names>
</name>
</person-group>. <article-title>More than just attractive: how CCL2 influences myeloid cell behavior beyond chemotaxis</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<elocation-id>2759</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.02759</pub-id>
</citation>
</ref>
<ref id="B43">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duell</surname> <given-names>BL</given-names>
</name>
<name>
<surname>Cripps</surname> <given-names>AW</given-names>
</name>
<name>
<surname>Schembri</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Ulett</surname> <given-names>GC</given-names>
</name>
</person-group>. <article-title>Epithelial cell coculture models for studying infectious diseases: Benefits and limitations</article-title>. <source>J Biomed Biotechnol</source>. (<year>2011</year>) <volume>852419</volume>:<page-range>1&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2011/852419</pub-id>
</citation>
</ref>
<ref id="B44">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Josi&#x107;</surname> <given-names>K</given-names>
</name>
<name>
<surname>L&#xf3;pez</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Ott</surname> <given-names>W</given-names>
</name>
<name>
<surname>Shiau</surname> <given-names>LJ</given-names>
</name>
<name>
<surname>Bennett</surname> <given-names>MR</given-names>
</name>
</person-group>. <article-title>Stochastic delay accelerates signaling in gene networks</article-title>. <source>PloS Computational Biology</source>. (<year>2011</year>) <volume>7</volume> (<issue>11</issue>).doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pcbi.1002264</pub-id>
</citation>
</ref>
<ref id="B45">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gedeon</surname> <given-names>T</given-names>
</name>
<name>
<surname>Bokes</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Delayed protein synthesis reduces the correlation between mRNA and protein fluctuations</article-title>. <source>Biophysical Journal</source>. (<year>2012</year>) <volume>103</volume>(<issue>3</issue>):<page-range>377&#x2013;85</page-range>.</citation>
</ref>
<ref id="B46">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>JY</given-names>
</name>
<name>
<surname>Liao</surname> <given-names>CH</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Tan</surname> <given-names>YJ</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>R</given-names>
</name>
<name>
<surname>Qiu</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway</article-title>. <source>Virus Res</source>. (<year>2020</year>) <volume>286</volume>:<elocation-id>198074</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.virusres.2020.198074</pub-id>
</citation>
</ref>
<ref id="B47">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chow</surname> <given-names>MYT</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>RYK</given-names>
</name>
<name>
<surname>Chan</surname> <given-names>HK</given-names>
</name>
</person-group>. <article-title>Inhalation delivery technology for genome-editing of respiratory diseases</article-title>. <source>Advanced Drug Delivery Rev</source>. (<year>2021</year>) <volume>168</volume>:<page-range>217&#x2013;28</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.addr.2020.06.001</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>